More Telix Pharmaceuticals Limited news
Telix Pharmaceuticals LimitedASX: TLX

Receipt of $11.4M R&D tax rebate

Jul 21, 2020 at 12:29 AM EDT · Issued by Telix Pharmaceuticals Limited

Filed with ASX · Jul 21, 2020 at 12:29 AM EDT · 1 page · English

On 6ix: 6ix.com/news/receipt-of-dollar11.4m-randd-tax-rebate

Watch Telix Pharmaceuticals' latest call↗Telix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call · Replay · Aug 20Read the transcript of Telix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call↗

Telix Pharmaceuticals Limited on 6ix

Earlier from Telix Pharmaceuticals

  • FDA grants breakthrough designation for TLX250-CDx productJun 30, 2020
  • S&P DJI Announces June 2020 Quarterly RebalanceJun 11, 2020
  • Appendix 4C and Activity Report March 2020 quarterApr 20, 2020
  • Commercial Distribution Agmt for Prostate Cancer DiagnosticApr 8, 2020
  • Telix completes acquisition of licensed production facilityApr 2, 2020

Later from Telix Pharmaceuticals

  • Appendix 4C and Activities Report - June 2020 quarterJul 26, 2020
  • Report for half-year to 30 June 2020Aug 20, 2020
  • FDA grants orphan drug designation for TLX102Aug 30, 2020
  • IRE Distribution Partnership for Prostate Cancer ImagingAug 31, 2020
  • Strategic Collaboration with Varian for Prostate ImagingSep 2, 2020
All Telix Pharmaceuticals news releases↗

Follow Telix Pharmaceuticals into a list and get an email when it puts out news.

Follow Telix Pharmaceuticals
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer